| pubmed-article:19165429 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19165429 | lifeskim:mentions | umls-concept:C0038454 | lld:lifeskim |
| pubmed-article:19165429 | lifeskim:mentions | umls-concept:C0004057 | lld:lifeskim |
| pubmed-article:19165429 | lifeskim:mentions | umls-concept:C0012582 | lld:lifeskim |
| pubmed-article:19165429 | lifeskim:mentions | umls-concept:C0475224 | lld:lifeskim |
| pubmed-article:19165429 | lifeskim:mentions | umls-concept:C0010181 | lld:lifeskim |
| pubmed-article:19165429 | lifeskim:mentions | umls-concept:C0679699 | lld:lifeskim |
| pubmed-article:19165429 | lifeskim:mentions | umls-concept:C1708528 | lld:lifeskim |
| pubmed-article:19165429 | lifeskim:mentions | umls-concept:C1705117 | lld:lifeskim |
| pubmed-article:19165429 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:19165429 | pubmed:dateCreated | 2009-1-23 | lld:pubmed |
| pubmed-article:19165429 | pubmed:abstractText | The aim of secondary prevention in stroke is to avoid restrokes. The current standard treatment in Germany is a lifelong therapy with low-dose acetylsalicylic acid (ASA). As the incidence of restrokes remains relatively high from a health-care payer's perspective, the question arises, whether the combination of dipyridamole + acetylsalicylic acid (Dip + ASA) is cost-effective in comparison with a therapy based on ASA only. | lld:pubmed |
| pubmed-article:19165429 | pubmed:language | ger | lld:pubmed |
| pubmed-article:19165429 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19165429 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19165429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19165429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19165429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19165429 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19165429 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:19165429 | pubmed:issn | 0723-5003 | lld:pubmed |
| pubmed-article:19165429 | pubmed:author | pubmed-author:MittendorfTho... | lld:pubmed |
| pubmed-article:19165429 | pubmed:author | pubmed-author:GrondMartinM | lld:pubmed |
| pubmed-article:19165429 | pubmed:author | pubmed-author:ClaesChristaC | lld:pubmed |
| pubmed-article:19165429 | pubmed:author | pubmed-author:von der... | lld:pubmed |
| pubmed-article:19165429 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19165429 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:19165429 | pubmed:volume | 103 | lld:pubmed |
| pubmed-article:19165429 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19165429 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19165429 | pubmed:pagination | 778-87 | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:meshHeading | pubmed-meshheading:19165429... | lld:pubmed |
| pubmed-article:19165429 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:19165429 | pubmed:articleTitle | [Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke]. | lld:pubmed |
| pubmed-article:19165429 | pubmed:affiliation | Forschungsstelle für Gesundheitsökonomie, Leibniz Universität Hannover, Hannover, Germany. cc@ivbl.uni-hannover.de | lld:pubmed |
| pubmed-article:19165429 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19165429 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:19165429 | pubmed:publicationType | English Abstract | lld:pubmed |
